12:00 AM
 | 
Jun 11, 2012
 |  BioCentury  |  Tools & Techniques

Assembling around Ensemblins

Genentech is Ensemble's newest partner looking for macrocycle therapeutics

Ensemble Therapeutics Corp. thinks its DNA-Programmed Chemistry discovery technology is more efficient than competing platforms in the macrocycle space. The biotech now has its third major partnership, a d eal with Genentech Inc. to try to raise drugs against challenging targets in the Roche unit's preclinical pipeline.

Ensemble will receive an undisclosed upfront payment and is eligible for milestones and royalties. Genentech is not disclosing the precise targets, but did say it wants to generate macrocyclic agents that address protein-protein interactions.

Macrocycles are a class of organic compound featuring a ring structure found in many natural products. They typically range in size from 500-2,000 Da., making them larger than most small molecules but smaller than biologics.

Ensemble's DNA-Programmed Chemistry (DPC) discovery platform synthesizes molecules, dubbed Ensemblins, with cyclic backbones that typically range in size from 600 to 1,000 Da. (see SciBX:Science-Business...

Read the full 697 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >